Biocon Secures Health Canada Approval for Yesintek Autoinjector Pen

Biocon Limited's Canadian subsidiary has received a Notice of Compliance (NOC) from Health Canada for the Yesintek (ustekinumab) Autoinjector Pen, available in 45 mg and 90 mg dosages. The approval date was July 29, 2026.

What just happened

Health Canada has approved a new autoinjector pen format for Biocon's immunology drug Yesintek (ustekinumab). This follows previous approvals for subcutaneous injection and IV formulations in Canada.

Why this matters

The autoinjector pen offers a novel treatment delivery system for patients in Canada, differentiating Biocon's product from the originator and potentially driving market adoption across various care settings.

The backstory

Biocon had previously obtained authorization for Yesintek solution for subcutaneous injection (45 mg and 90 mg) and Yesintek I.V. (130 mg) in Canada in October 2025. This new approval expands their product offering in the immunology space.

What changes now

Biocon can now market and sell the Yesintek Autoinjector Pen in Canada, providing an alternative administration method for patients suffering from autoimmune conditions.

Risks to watch

Market adoption of the new autoinjector pen format and its uptake compared to existing treatment options will be key factors to monitor.

Peer comparison

The originator product in the Canadian market does not currently offer an autoinjector pen format, providing Biocon a competitive edge with this specific delivery system.

Context metrics (time-bound)

Approval date for the autoinjector pen: July 29, 2026. Prior approvals for other Yesintek formats: October 2025.

What to track next

Investors will be watching the commercial performance of the Yesintek Autoinjector Pen in Canada and its contribution to Biocon's immunology franchise growth.

Reader Takeaway: Differentiated product format approved; market adoption key for growth.